Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting
The drop-the-losers design combines a phase 2 trial of k treatments and a confirmatory phase 3 trial under a single adaptive protocol, thereby gaining efficiency over a traditional clinical development approach. Such designs may be particularly useful in the rare disease setting, where conserving sample size is paramount, and control arms may not be feasible. We propose an unconditional exact likelihood (UEL) testing and inference procedure for these designs for a binary endpoint using small sample sizes, comparing its operating characteristics to existing methods. Additional practical considerations are evaluated, including the choice of stagewise sample sizes and effect of ties.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Journal of biopharmaceutical statistics - 31(2021), 4 vom: 04. Juli, Seite 507-522 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jazić, Ina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive design |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 25.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/10543406.2021.1918139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326020497 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326020497 | ||
| 003 | DE-627 | ||
| 005 | 20231225193704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10543406.2021.1918139 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1086.xml |
| 035 | |a (DE-627)NLM326020497 | ||
| 035 | |a (NLM)34053399 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jazić, Ina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 25.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The drop-the-losers design combines a phase 2 trial of k treatments and a confirmatory phase 3 trial under a single adaptive protocol, thereby gaining efficiency over a traditional clinical development approach. Such designs may be particularly useful in the rare disease setting, where conserving sample size is paramount, and control arms may not be feasible. We propose an unconditional exact likelihood (UEL) testing and inference procedure for these designs for a binary endpoint using small sample sizes, comparing its operating characteristics to existing methods. Additional practical considerations are evaluated, including the choice of stagewise sample sizes and effect of ties | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adaptive design | |
| 650 | 4 | |a binary endpoint | |
| 650 | 4 | |a drop-the-losers design | |
| 650 | 4 | |a interim analysis | |
| 650 | 4 | |a rare disease | |
| 650 | 4 | |a small sample size | |
| 650 | 4 | |a two-stage design | |
| 700 | 1 | |a Liu, Xiaoyan |e verfasserin |4 aut | |
| 700 | 1 | |a Laird, Glen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biopharmaceutical statistics |d 1991 |g 31(2021), 4 vom: 04. Juli, Seite 507-522 |w (DE-627)NLM012811432 |x 1520-5711 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:4 |g day:04 |g month:07 |g pages:507-522 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10543406.2021.1918139 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 4 |b 04 |c 07 |h 507-522 | ||